Travere Therapeutics Inc (NAS:TVTX)
$ 7.23 -0.6 (-7.66%) Market Cap: 550.41 Mil Enterprise Value: 559.06 Mil PE Ratio: 0 PB Ratio: 7.45 GF Score: 58/100

Retrophin Inc Announces Agreement to Acquire Orphan Technologies Conference Call Transcript

Oct 22, 2020 / 09:00PM GMT
Release Date Price: $21.08 (+2.28%)
Operator

Ladies and gentlemen, thank you for standing by. Welcome to the Retrophin Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions) I would now like to hand the conference over to your speaker today, Mr. Chris Cline, SVP, Investor Relations and Corporate Communications. Thank you. Please go ahead.

Chris Cline
Retrophin, Inc. - VP of IR & Corporate Communications

Great. Thank you, Jimmy. Good afternoon, and thank you all for joining us on short notes today to talk about our agreement to acquire Orphan Technologies and their OT-58 program. A copy of the press release announcing the agreement as well as slides that outline our discussion today are available on our website and as part of our webcast.

Today's call will be led by our Chief Executive Officer, Dr. Eric Dube. Eric will be joined for the prepared remarks by Dr. Bill Rote, Senior Vice President of Research and Development; and our Chief Financial Officer, Laura Clague, will join us for the Q&A session.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot